While flu and COVID-19 dominate headlines, a silent threat lurks: RSV. This common respiratory virus, often dismissed as a mere cold, is the leading cause of hospitalization in infants and poses a serious risk to older adults. But here's the surprising part: public awareness of RSV vaccines and antibody injections is on the rise, even as a controversial shift in childhood vaccination policies unfolds.
Amidst a particularly harsh flu season and a COVID-19 resurgence, another respiratory illness, Respiratory Syncytial Virus (RSV), is quietly surging. The Centers for Disease Control and Prevention (CDC) reports elevated RSV cases across the country, with a concerning spike in emergency room visits and hospitalizations for children under four, as highlighted by the Center for Infectious Disease Research & Policy (CIDRAP). The Pan American Health Organization's recent alert warns of a gradual upward trend in RSV activity, potentially exacerbating the strain on already burdened healthcare systems, especially when combined with flu cases.
RSV, though often mild, can be devastating. While most cases resolve on their own, it's the leading cause of hospitalization for infants in the U.S. and poses a significant threat to older adults. The CDC estimates over 100,000 hospitalizations annually among older Americans and 58,000 or more among infants and young children.
But there's hope. In 2023, the U.S. approved two groundbreaking RSV immunizations: vaccines for older adults and pregnant individuals (to protect newborns), and a monoclonal antibody injection for newborns and infants.
A recent survey by the Annenberg Public Policy Center (APPC) reveals a heartening trend: growing public awareness of these life-saving interventions. The survey, conducted in late 2025, found that a majority of Americans are now familiar with RSV immunizations, and a significant portion (6 in 10) would recommend them to those at risk, a marked increase from previous years.
However, this progress is overshadowed by a controversial move. Under the leadership of Health and Human Services (HHS) Secretary Robert F. Kennedy Jr., a known vaccine critic, the U.S. has drastically reduced the number of routinely recommended childhood vaccinations from 17 to 11, sparking widespread debate. While RSV immunization, being an antibody product, isn't directly affected by this reduction, its presentation as a tool reserved for high-risk groups raises questions.
Interestingly, the survey highlights a nuanced understanding of RSV prevention. Awareness of the RSV vaccine for older adults has jumped from 42% in 2023 to 56% in 2025. Similarly, knowledge of the maternal RSV vaccine to protect newborns has risen from 12% in 2023 to 38% in the latest survey.
And this is the part most people miss: The public is increasingly likely to recommend these interventions. 64% would recommend the RSV vaccine to older adults, 61% to pregnant individuals, and 59% would suggest the antibody injection for newborns whose mothers weren't vaccinated during pregnancy.
The survey also reveals a strong preference for the RSV vaccine over the antibody injection for pregnant women, with 43% favoring the vaccine compared to 13% for the injection. This shift in preference, coupled with the growing awareness, underscores the public's evolving understanding of RSV prevention.
But the question remains: Is this enough? While the increased awareness is encouraging, the reduction in childhood vaccinations and the ongoing debate surrounding vaccine safety raise concerns.
The survey also highlights a crucial perception: most Americans believe the RSV vaccine is safer than contracting the virus itself. 70% consider it safer for older adults, and 58% for pregnant individuals.
So, what does this mean for the future of RSV prevention?
The rise in public awareness and willingness to recommend RSV interventions is a positive step. However, the controversial changes to childhood vaccination policies and lingering vaccine hesitancy present significant challenges.
What do you think? Is the public's growing awareness of RSV immunizations enough to combat the virus's impact? How should we address the concerns surrounding vaccine safety and the reduction in childhood vaccinations? Share your thoughts in the comments below.
